Vlado Perkovic's Publications

About Vlado Perkovic's Publications

Board Member
  • MBBS,
  • PhD,
  • FASN,
  • FRACP

  • Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials

    The Lancet Diabetes & Endocrinology Date published:

  • Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy

    New England Journal of Medicine Date published:

  • Assessing the Quality of Care for People with CKD: A Systematic Review and Meta-Analysis

    Journal of the American Society of Nephrology Date published:

  • Risk-Based Implementation of SGLT2 Inhibitors: Insights from the CANVAS Program and CREDENCE Trial

    Journal of the American Society of Nephrology Date published:

  • Cardiovascular, Kidney, and Safety Outcomes with Canagliflozin in Older Adults: A Pooled Secondary Analysis of the CANVAS Program and CREDENCE Trial

    Journal of the American Society of Nephrology Date published:

  • Prognostic Enrichment Using the Klinrisk Model: Insights from Landmark Kidney Disease Clinical Trials

    Journal of the American Society of Nephrology Date published:

  • Safety and Efficacy of Iptacopan in Patients with IgA Nephropathy with Baseline eGFR 20 to <30 mL/min: Phase 3 APPLAUSE-IgAN Subcohort Results

    Journal of the American Society of Nephrology Date published:

  • Effect of Iptacopan on Proteinuria and Complement Biomarkers in IgAN: Interim Analysis of the Phase 3 APPLAUSE-IgAN Study

    Journal of the American Society of Nephrology Date published:

  • Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of CKD Severity in the FLOW Trial

    Journal of the American Society of Nephrology Date published:

  • Effect of Semaglutide on Mortality Outcomes in the FLOW Trial

    Journal of the American Society of Nephrology Date published:

  • Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: a participant level pooled analysis of CREDENCE and CANVAS

    European Heart Journal Date published:

  • Bidirectional relationship between kidney disease progression and cardiovascular events in type 2 diabetes: new Insights from the CANVAS Program and CREDENCE trial

    European Heart Journal Date published:

  • Kidney Disease as a Cardiovascular Disease Priority

    Circulation Date published:

  • Canagliflozin and iron metabolism in the CREDENCE trial

    Nephrology Dialysis Transplantation Date published:

  • Cardiovascular, Kidney and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis

    Circulation Date published:

  • Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial

    European Heart Journal Date published: